1. Pink Sheet
  2. >>R&D

War on C Difficile Is Being Fought On Multiple Fronts

 
• By Bridget Silverman

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.

Clostridium difficile bacteria isolated on black background, 3D illustration. Bacteria which cause pseudomembraneous colitis and are associated with nosocomial antibiotic resistance - Illustration

While the fight against antimicrobial resistance often produces more lamentation than new products, some long-stalled therapies for the notoriously challenging bacteria Clostridium difficile have recently shown new signs of life.

Funding from the US government, through the Biomedical Advanced R&D Agency (BARDA), helped Summit Therapeutics PLC start its Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

UK Budget: Little Mention Of Pharma, But Some Support For Innovators

 
• By Eliza Slawther

The UK’s autumn budget failed to introduce any widespread changes for pharma, but scale-ups and innovators could benefit from changes to enterprise and investment schemes. Some industry voices warn of underinvestment in the MHRA and innovative medicines.

Who Does What? EU RADIAL Study Exposes Oversight Challenges In Decentralized Trials

 
• By Vibha Sharma

Decentralizing clinical research demands rethinking accountability and logistics to prevent gaps that could compromise safety and trial integrity.

France To Offer 14-Day Clinical Trial Reviews To Attract Research

 
• By Francesca Bruce

France is set to pilot a new fast-track process that could more than halve the timeline for authorizing certain clinical trial applications.

Europe’s Trials@Home Findings Show Remote Recruitment Is Complicated

 
• By Vibha Sharma

Europe’s RADIAL study comparing fully decentralized, hybrid and conventional trial approaches reveals why online recruitment is not simple.

More from Pink Sheet

Trump’s Semaglutide Most Favored Nation Price Will ‘Supersede’ Medicare MFP

 
• By Cathy Kelly

The Medicare negotiated price is slightly higher than the Most Favored Nation price recently announced by the Trump Administration.

AI Boosts Parkinson’s Disease Cell Therapy Development

 
• By Bridget Silverman

Aspen Neurosciences and BlueRock Therapeutics see hope for artificial intelligence to improve the quality of cell therapies to replace dopaminergic neurons in Parkinson's disease.

PhRMA Urges Japan To Maintain Drug Prices Amid MFN Concerns

 
• By Lisa Takagi

While Japan tries to balance its healthcare costs, the major US industry group is concerned reimbursement pricing practices in the country could influence US levels under Trump's MFN policy.